Publications by authors named "Bridget Ady"
Article Synopsis
- The TAME trial is a phase 3 clinical study investigating the effects of targeted therapeutic mild hypercapnia on brain injury in comatose adults revived from out-of-hospital cardiac arrest.
- It involves randomly assigning 1700 participants in various countries to either receive mild hypercapnia or maintain normal levels of carbon dioxide in their blood for 24 hours after resuscitation.
- The main goal is to measure and compare the participants' functional outcomes at 6 months using the Glasgow Outcome Scale-Extended, alongside evaluating mortality, cognitive function, and quality of life as secondary outcomes.
Article Synopsis
- Guidelines suggest maintaining normal carbon dioxide levels for adults in a coma resuscitated from cardiac arrest, but mild higher levels may help increase brain blood flow and improve outcomes.
- In a study involving 1,700 patients, participants were randomly assigned to either mild hypercapnia or normocapnia for 24 hours and were assessed 6 months later for neurologic recovery.
- Results showed no significant difference in favorable neurological outcomes or mortality between the two groups, indicating that mild hypercapnia did not improve recovery compared to normal levels.
Objectives: Trials comparing the effects of transfusing RBC units of different storage durations have considered mortality or morbidity as outcomes. We perform the first economic evaluation alongside a full age of blood clinical trial with a large population assessing the impact of RBC storage duration on quality-of-life and costs in critically ill adults.
Design: Quality-of-life was measured at 6 months post randomization using the EuroQol 5-dimension 3-level instrument.
Article Synopsis
- - A study was conducted on critically ill adults to determine if the duration of red blood cell storage affects mortality rates after transfusions, comparing fresh (short-term) red cells to standard older (long-term) ones.
- - The trial included nearly 4,919 patients from multiple countries, with 90-day mortality rates showing no significant difference between those receiving fresh red cells (24.8% deaths) and older red cells (24.1% deaths).
- - Ultimately, the research concluded that the age of the transfused red cells did not influence mortality outcomes at 90 days post-transfusion.
Article Synopsis
- - This study aims to investigate whether using the freshest available red blood cells (RBCs) instead of standard RBCs can lower mortality rates in critically ill ICU patients, making it the largest ongoing randomized controlled trial on this topic.
- - Conducted as a double-blind trial involving 5000 adult ICU patients across multiple countries, the study compares the effects of fresh RBC transfusions on various health outcomes, including 90-day all-cause mortality.
- - With a robust statistical plan in place for unbiased results, the TRANSFUSE trial is designed to potentially influence clinical practices and policies regarding blood transfusions in critical care, regardless of its findings.